Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
CA Regulators Complete Review of Wildfire Risk Model California’s Department of Insurance has completed a review of the state’s first wildfire catastrophe model, which property/casualty insurers...
Trump Administration’s ‘AI Action Plan’ Targets State AI Regulation The Trump administration released an “AI Action Plan,” aimed at speeding the development of artificial...
In the span of just 36 days this spring and summer, the number of states offering unemployment benefits to striking workers doubled—to four. New Jersey was the first to offer such benefits, beginning...
Developing Anti-‘Debanking’ Trend in Red States? A new front appears to have opened in the ongoing battle over environmental, social and governance (ESG) investing. In March Idaho Gov. Brad...
FL Requests Medicaid Waiver to Bolster Health Workforce Florida is seeking a federal waiver to use Medicaid funding to expand its health care workforce, a plan that could be adopted by other states....
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.